Gene therapy shows signs of delayed progression in fatal neurodegenerative disease. A single intravenous infusion of adeno-associated virus serotype 9 encoding beta-galactosidase (AAV9-GLB1) has been associated with short-term adverse effects. The therapy led to increased levels of beta-galactosidase in the body. Signs of delayed disease progression were observed. A study published on MedPage Today confirms these findings in patients with this fatal disease.